Stockholders' Equity (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2021

Dec. 31, 2020

Stockholders' Equity (Deficit)

Schedule of stock options activity

		Weighted		Weighted
		Average		Average	Aggregate
	Number of	Exercise		Remaining	Intrinsic
	Shares	Price		Term	Value
Balance as of December 31, 2020	32,127	$	1.96	5.01	$	19,248
Granted	2,028		2.79
Exercised	(798)		0.73
Forfeited	(7,738)		2.97
Expired	(1,603)		2.78
Balance as of September 30, 2021	24,016	$	1.69	2.59	$	25,699
Expected to vest at September 30, 2021	2,357	$	2.74	9.35		—
Exercisable at September 30, 2021	24,016	$	1.69	2.59	$	25,699

		Weighted		Weighted
		Average		Average	Aggregate
	Number of	Exercise		Remaining	Intrinsic
	Shares	Price		Term	Value
Balance as of December 31, 2019	35,016	$	2.00	5.03	$	24,634
Granted	335		2.46	—		—
Exercised	(230)		0.62	—		—
Forfeited	(1,700)		2.86	—		—
Expired	(1,294)		2.22	—		—
Balance as of December 31, 2020	32,127	$	1.96	5.01	$	19,248
Expected to vest at December 31, 2020	8,427	$	2.94	7.98		—
Exercisable at December 31, 2020	24,611	$	1.65	4.12	$	19,248

Schedule of the restricted stock unit activity

		Weighted Average
		Grant-Date Fair
	Shares	Value
Outstanding as of December 31, 2020	8,268	$	2.61
Granted	9,260		2.81
Vested	—		—
Forfeited	(359)		2.70
Outstanding as of September 30, 2021	17,169	$	2.71

A summary of the restricted stock unit activity is presented below (in thousands, except per share amounts):

		Weighted Average
		Grant-Date Fair
	Shares	Value
Outstanding as of December 31, 2019	8,433	$	2.63
Granted	1,003		2.38
Vested	—		—
Forfeited	(1,168)		2.67
Outstanding as of December 31, 2020	8,268	$	2.61

Schedule of share based compensation expense

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Cost of revenue, excluding depreciation and amortization	$	388	$	54	$	543	$	61
Sales and marketing		37		28		98		31
General and administrative		59		221		160		872
Research and development		19		24		49		24
	$	503	$	327	$	850	$	988